Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?-Reference-Cited by-同舟云学术

Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?

Published:2023-02-22 Issue:5 Volume:270 Page:2702-2714
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Smolenschi Cristina^ORCID,Rassy Elie,Pallud Johan,Dezamis Edouard,Copaciu Razvan,Parker Fabrice,Garcia Gabriel,Lezghed Naima,Colomba Emeline,Khettab Mohamed,Ammari Sami,Fekhi Mohamed,Martanovschi Larisa,Benadhou Lina,Knafo Steven,Guyon David,Cheaib Bianca,Dhermain Frederic,Dumont Sarah Naomie

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s00415-023-11600-w.pdf

Reference59 articles.

1. Stupp R, Masson WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

2. Koshy M, Villano JL, Dolecek TA et al (2012) Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol 107:207–212

3. Di Carlo DT, Cagnazzo F, Benedetto N, Morganti R, Perrini P (2017) Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis. Neurosurg Rev. https://doi.org/10.1007/s10143-017-0928-7

4. Bahadur S, Sahu AK, Baghel P et al (2019) Current promising treatment strategy for glioblastoma multiform: a review. Oncol Rev 13(2):417

5. Chen S, Le T, Harley BAC, Imoukhuede PI (2018) Characterizing glioblastoma heterogeneity via single-cell receptor quantification. Front Bioeng Biotechnol 6:92

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials;Frontiers in Medicine;2024-07-02

2. Promising outcome of patients with recurrent glioblastoma after Gamma Knife-based hypofractionated radiotherapy;Neurochirurgie;2024-03

3. Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment;Frontiers in Chemistry;2024-01-08

4. Bevacizumab;Reactions Weekly;2023-06-10

5. Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors;Scientific Reports;2023-06-09